Ranbaxy Seeks Nexium Generic API Sources In Face Of Nearby Launch
This article was originally published in PharmAsia News
Ranbaxy Laboratories is discussing with at least two companies with U.S. FDA-approved factories to supply it with the active pharmaceutical ingredients it relies on for its generic of AstraZeneca's Nexium (esomeprazole) for treating heartburn.
You may also be interested in...
The European Commission has unexpectedly concluded that CBD should not be considered as drug opening up the path to regulated EU market for the cannabinoid as a novel food.
As Apotex names its new US president and CEO, Akorn puts together a fresh board of directors following bankruptcy proceedings. Stada has made new appointments in Germany, while Siegfried makes significant changes in its leadership roles.
A WHO recommendation to explicitly exempt low-THC CBD from international narcotics controls has been emphatically rejected by UN member states. The CBD industry had hoped for a positive outcome to remove regulatory pressure on product manufacturers in Europe and around the world.